Literature DB >> 8882085

The role of recombinant human DNase in the treatment of patients with cystic fibrosis: many promises, more problems.

M S Zach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8882085      PMCID： PMC472501          DOI： 10.1136/thx.51.7.750

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  44 in total

1.  Aerosolized pancreatic dornase and antibiotics in pulmonary infections: use in patients with postoperative and nonoperative infections.

Authors:  R SPIER; E WITEBSKY; J R PAINE
Journal:  JAMA       Date:  1961-12-02       Impact factor: 56.272

2.  In-vitro evaluation of effect of enzymes on tracheobronchial secretions from patients withcystic fibrosis.

Authors:  W S CHERNICK; G J BARBERO; H J EICHEL
Journal:  Pediatrics       Date:  1961-04       Impact factor: 7.124

3.  Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production.

Authors:  B Oberwaldner; B Theissl; A Rucker; M S Zach
Journal:  Eur Respir J       Date:  1991-02       Impact factor: 16.671

4.  Rheological properties controlling mucociliary frequency and respiratory mucus transport.

Authors:  E Puchelle; J M Zahm; D Quemada
Journal:  Biorheology       Date:  1987       Impact factor: 1.875

5.  Effects of combined treatment with rhDNase and airflow oscillations on spinnability of cystic fibrosis sputum in vitro.

Authors:  B Dasgupta; R P Tomkiewicz; W A Boyd; N E Brown; M King
Journal:  Pediatr Pulmonol       Date:  1995-08

6.  Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

Authors:  B W Ramsey; S J Astley; M L Aitken; W Burke; A A Colin; H L Dorkin; J D Eisenberg; R L Gibson; I R Harwood; D V Schidlow
Journal:  Am Rev Respir Dis       Date:  1993-07

Review 7.  Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.

Authors:  H M Bryson; E M Sorkin
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

8.  Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis.

Authors:  W E Regelmann; C M Siefferman; J M Herron; G R Elliott; C C Clawson; B H Gray
Journal:  Pediatr Pulmonol       Date:  1995-01

9.  Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis.

Authors:  A L Smith; G Redding; C Doershuk; D Goldmann; E Gore; B Hilman; M Marks; R Moss; B Ramsey; T Rubio
Journal:  J Pediatr       Date:  1988-04       Impact factor: 4.406

10.  Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.

Authors:  J M Zahm; S Girod de Bentzmann; E Deneuville; C Perrot-Minnot; A Dabadie; F Pennaforte; M Roussey; S Shak; E Puchelle
Journal:  Eur Respir J       Date:  1995-03       Impact factor: 16.671
View more
  2 in total

1.  Chelation of Membrane-Bound Cations by Extracellular DNA Activates the Type VI Secretion System in Pseudomonas aeruginosa.

Authors:  Mike Wilton; Megan J Q Wong; Le Tang; Xiaoye Liang; Richard Moore; Michael D Parkins; Shawn Lewenza; Tao G Dong
Journal:  Infect Immun       Date:  2016-07-21       Impact factor: 3.441

2.  Long-term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis.

Authors:  C E Milla
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.